Back to today’s briefing

Story perspectives

CEL-SCI's Multikine Immunotherapy Promises 73% Survival Rate

7/31/2025

50 10

Summary

Story summary

CEL-SCI Corporation is making waves in the fight against head and neck cancer with its groundbreaking immunotherapy, Multikine, boasting a remarkable 73% five-year survival rate in trials. In an exciting collaboration with Saudi Arabia, the company aims to fast-track regulatory approval, supporting the Kingdom's Vision 2030 to revolutionize biotechnology and healthcare access across the MENA region.

1 of 1

Story summary

CEL-SCI Corporation is making waves in the fight against head and neck cancer with its groundbreaking immunotherapy, Multikine, boasting a remarkable 73% five-year survival rate in trials. In an exciting collaboration with Saudi Arabia, the company aims to fast-track regulatory approval, supporting the Kingdom's Vision 2030 to revolutionize biotechnology and healthcare access across the MENA region.